A new artificial intelligence model called COMPASS, developed by Harvard Medical School researchers and their colleagues, improves prediction of which patients are most likely to respond to ICIs.
The researchers trained COMPASS using data from 10,184 tumors across 33 cancer types derived from the Cancer Genome Atlas, a public database containing genetic sequence and molecular data from primary cancer and matched normal samples.
Their results showed that COMPASS outperformed the best existing approach for predicting ICI response by nearly 10% on average.
This boost in accuracy held true under a variety of conditions, including for different cancer types, ICI drugs, gene transcript sequencing platforms and biopsy sites.
It makes its predictions based on patients' tumor gene activity and provides a rationale for its output.
Because the results were interpretable, the team could explain unexpected results among ICI response outliers.
【MORE】